Literature DB >> 20920751

Cancer epigenome.

Matthias Lechner1, Chris Boshoff, Stephan Beck.   

Abstract

Cancer is a heterogeneous disease caused largely by abnormalities of the genome and the epigenome. Typically, such abnormalities include genetic changes such as mutations and other genomic rearrangements or epigenetic changes such as aberrant DNA methylation and histone modifications that are frequently mediated by exposure to environmental or lifestyle factors. Therefore, comprehensive genetic and epigenetic analysis of cancer genomes is the most effective way to identify causative changes involved in tumorigenesis, irrespective of whether they are inherited or acquired. In this chapter, we review recent progress in the field and discuss some of the pilot studies that have already established epigenomic analysis as integral part of modern cancer research and present a major step toward personalized treatment of this disease in the future.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20920751     DOI: 10.1016/B978-0-12-380866-0.60009-5

Source DB:  PubMed          Journal:  Adv Genet        ISSN: 0065-2660            Impact factor:   1.944


  15 in total

Review 1.  Bridging epigenomics and complex disease: the basics.

Authors:  Raffaele Teperino; Adelheid Lempradl; J Andrew Pospisilik
Journal:  Cell Mol Life Sci       Date:  2013-03-06       Impact factor: 9.261

Review 2.  The de novo DNA methyltransferase DNMT3A in development and cancer.

Authors:  Bi-Feng Chen; Wai-Yee Chan
Journal:  Epigenetics       Date:  2014-03-03       Impact factor: 4.528

3.  Tumor suppressor gene BLU is frequently downregulated by promoter hypermethylation in myelodysplastic syndrome.

Authors:  Yujuan Yang; Qingxia Zhang; Feng Xu; Lingyun Wu; Qi He; Xiao Li
Journal:  J Cancer Res Clin Oncol       Date:  2012-01-15       Impact factor: 4.553

4.  Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation.

Authors:  Heike Peterziel; Julia Müller; Andreas Danner; Sebastian Barbus; Hai-Kun Liu; Bernhard Radlwimmer; Torsten Pietsch; Peter Lichter; Günther Schütz; Jochen Hess; Peter Angel
Journal:  Neuro Oncol       Date:  2012-03-06       Impact factor: 12.300

Review 5.  Epigenome-wide association studies for common human diseases.

Authors:  Vardhman K Rakyan; Thomas A Down; David J Balding; Stephan Beck
Journal:  Nat Rev Genet       Date:  2011-07-12       Impact factor: 53.242

Review 6.  Advancing neuroscience through epigenetics: molecular mechanisms of learning and memory.

Authors:  David L Molfese
Journal:  Dev Neuropsychol       Date:  2011       Impact factor: 2.253

7.  Variation in DNA methylation of human blood over a 1-year period using the Illumina MethylationEPIC array.

Authors:  Ina Zaimi; Dong Pei; Devin C Koestler; Carmen J Marsit; Immaculata De Vivo; Shelley S Tworoger; Alexandra E Shields; Karl T Kelsey; Dominique S Michaud
Journal:  Epigenetics       Date:  2018-10-21       Impact factor: 4.528

8.  Epigenetic influences in the aetiology of cancers arising from breast and prostate: a hypothesised transgenerational evolution in chromatin accessibility.

Authors:  Francis L Martin
Journal:  ISRN Oncol       Date:  2013-02-03

9.  RNF43 and PWWP2B inhibit cancer cell proliferation and are predictive or prognostic biomarker for FDA-approved drugs in patients with advanced gastric cancer.

Authors:  Sung-Hwa Sohn; Hee Jung Sul; Bohyun Kim; Hyeong Su Kim; Bum Jun Kim; Hyun Lim; Ho Suk Kang; Jae Seung Soh; Kab Choong Kim; Ji Woong Cho; Jinwon Seo; Youngho Koh; Dae Young Zang
Journal:  J Cancer       Date:  2021-06-01       Impact factor: 4.207

10.  Temporal stability of epigenetic markers: sequence characteristics and predictors of short-term DNA methylation variations.

Authors:  Hyang-Min Byun; Francesco Nordio; Brent A Coull; Letizia Tarantini; Lifang Hou; Matteo Bonzini; Pietro Apostoli; Pier Alberto Bertazzi; Andrea Baccarelli
Journal:  PLoS One       Date:  2012-06-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.